Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-06-21 Regulatory Filings
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획변경승인신청)(마이크로바이옴 면역항암 치료제 GEN-001의 위 또는 위식도 접합부 선암종 환자 대상 국내 제2상 임상시험계획 (IND) 변경승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding a change in clinical trial plans (IND amendment). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it details a specific regulatory update regarding clinical trials and does not fit into categories like financial reports, dividends, or shareholder meetings, it is best classified as a general Regulatory Filing (RNS).
2023-06-21 Korean
투자판단관련주요경영사항(임상시험계획변경승인)(마이크로바이옴 면역항암 치료제 GEN-001의 담도암 환자 대상 국내 제2상 임상시험계획 (IND) 변경승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the approval of a clinical trial plan change (IND amendment) for a drug candidate. Since this is a formal regulatory disclosure of a material event (clinical trial status) and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-06-01 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal corporate announcement regarding a change in the company's representative directors (CEO). It details the names of the outgoing and incoming directors, the reason for the change (resignation), and the effective date. This falls directly under the category of Board/Management Information.
2023-05-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, specifically noting the exclusion of a special related party due to resignation. This falls under the category of Major Shareholding Notification (MRQ).
2023-05-31 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding the scheduling and details of an Investor Relations (IR) presentation (기업설명회). It provides the date, time, location (online link), and the purpose of the meeting. Since it is an announcement of an upcoming presentation rather than the presentation deck itself, and it is under 5,000 characters, it falls under the category of a Report Publication Announcement or general regulatory filing regarding an event.
2023-05-18 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Genome & Company, covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.